Elisa Agostinetto: Very much awaited results of EMBER-3 at SABCS24
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on X:
“General session 1 at SABCS24 starts with the very much awaited results of EMBER-3.
3 co-primary endpoints:
- In ESR1-mut patients, imlunestrant high PFS vs. ET SoC
- No significant difference in all patients
- Imlunestrant and Abemaciclib high PFS (vs. Imlu) in all patients, regardless of ESR1-mutation.”
More posts featuring Elisa Agostinetto.
Read the post “Highlights from Day 1 of SABCS 2024” on oncodaily.com.
Dr. Elisa Agostinetto is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute.
Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023